Bioavailable Testosterone: At-Home and Finger-Prick Testing Options, Normal Ranges, and Optimal Levels

What Bioavailable Testosterone Actually Measures

Bioavailable testosterone is the sum of free testosterone plus albumin-bound testosterone. These two fractions can leave the bloodstream and enter cells. The remaining fraction, tightly bound to SHBG, is biologically inactive at the tissue level.

Understanding why this distinction matters requires a brief look at how testosterone circulates. Roughly 44 to 65 percent of circulating testosterone in men is bound to SHBG, 33 to 54 percent is loosely bound to albumin, and only 1 to 3 percent is completely unbound (free) [1]. Because albumin binds testosterone with low affinity, that fraction dissociates readily at the capillary bed and becomes available to tissues.

The Vermeulen Calculation

Most labs do not measure bioavailable testosterone directly with an immunoassay. Instead, they apply the Vermeulen equation, published in the Journal of Clinical Endocrinology and Metabolism in 1999, which uses measured total testosterone, SHBG, and albumin (assumed at 4.3 g/dL unless directly measured) to derive bioavailable and free testosterone values [2]. The calculation is validated against equilibrium dialysis, the gold-standard direct method.

Why Total Testosterone Alone Can Mislead

A man with a total testosterone of 450 ng/dL and an SHBG of 80 nmol/L has roughly the same bioavailable testosterone as a man with a total testosterone of 250 ng/dL and an SHBG of 25 nmol/L. Both may present with low-T symptoms despite one appearing "normal" on a total-T panel. The 2018 Endocrine Society Clinical Practice Guideline on male hypogonadism states: "We recommend measuring free testosterone concentration using reliable methods in men with total testosterone concentrations near the lower limit of the normal range and in men in whom alteration of SHBG is suspected" [3].

At-Home and Finger-Prick Testing Options

At-home testosterone testing has matured considerably since the early enzyme-linked immunoassay (ELISA) strips of the 2000s. Current dried blood spot (DBS) kits using liquid chromatography-tandem mass spectrometry (LC-MS/MS) can achieve analytical performance close to venipuncture reference methods.

Dried Blood Spot (DBS) Kits

DBS kits require a finger-prick lancet, a collection card, and a prepaid return envelope. The patient presses a fingertip to a cellulose filter card, air-dries the spot for 30 minutes, and mails it to a CLIA-certified laboratory. LC-MS/MS analysis of DBS samples for testosterone has demonstrated a coefficient of variation below 8 percent and a Pearson correlation of r = 0.96 against paired venous samples in published validation studies [4]. Several commercial panels include SHBG in the same DBS card, enabling the Vermeulen bioavailable testosterone calculation without a separate venous draw.

Saliva Testing

Salivary testosterone reflects free testosterone, not bioavailable testosterone. Saliva kits are widely marketed but have several limitations: salivary testosterone concentrations are roughly 1 to 2 percent of serum values, diurnal variation is amplified, food, bleeding gums, and topical testosterone contamination all inflate results. The Endocrine Society does not recommend saliva assays for routine androgen evaluation [3]. Salivary data cannot be plugged into the Vermeulen equation to produce a valid bioavailable testosterone figure.

Venous Draw (Reference Standard)

A standard venipuncture draw remains the most reproducible method. Blood drawn between 7 and 10 a.m. Captures the diurnal testosterone peak. Equilibrium dialysis for free testosterone, performed at specialized reference laboratories (Quest Diagnostics Nichols Institute, Mayo Clinic Laboratories), adds cost but provides the most accurate free-T value. Bioavailable testosterone can then be measured directly by ammonium sulfate precipitation, though this is less commonly ordered than the calculated value.

Choosing Between At-Home and Clinic Testing

At-home DBS kits are appropriate for initial screening, longitudinal monitoring during TRT, and situations where clinic access is limited. Clinic venipuncture is preferred for initial diagnostic workup (a borderline result warrants confirmation), when SHBG measurement by LC-MS/MS is needed for the Vermeulen calculation, and before making any dosing change greater than 20 percent. The CDC Hormone Standardization Program (HoSt) maintains a registry of labs that meet testosterone measurement accuracy standards, which is a useful filter when selecting an at-home kit provider [5].

Bioavailable Testosterone Normal Ranges by Age and Sex

Reference ranges vary by assay, laboratory, and population studied. The figures below come from the most cited large-scale studies and society-endorsed reference data.

Men

The Framingham Heart Study measured bioavailable testosterone in 1,632 community-dwelling men and published age-stratified reference intervals in 2011 [6]. Bioavailable testosterone declines about 2 to 3 percent per year after age 30, a steeper relative fall than total testosterone because SHBG rises with age.

| Age group | Bioavailable T (ng/dL) approximate range | |---|---| | 20 to 29 | 260 to 680 | | 30 to 39 | 220 to 580 | | 40 to 49 | 180 to 520 | | 50 to 59 | 140 to 430 | | 60 to 69 | 110 to 360 | | 70 and older | 80 to 280 |

These are population reference intervals, not treatment targets. A 65-year-old man with symptoms and a bioavailable testosterone of 90 ng/dL sits below the lower quartile of his age group, which supports clinical evaluation even if his total testosterone is in the 300s.

Women

Female bioavailable testosterone is substantially lower and varies across the menstrual cycle and menopausal status. The SWAN (Study of Women's Health Across the Nation) cohort provided reference data across reproductive and menopausal stages [7]. Premenopausal women typically show bioavailable testosterone between 0.5 and 8.5 ng/dL; postmenopausal women average 0.3 to 3.8 ng/dL. SHBG rises after menopause on oral estrogen therapy, which further reduces bioavailable testosterone even when total testosterone appears unchanged.

Children and Adolescents

Pediatric reference ranges differ substantially from adult values and depend on Tanner stage. Testing in individuals under 18 requires pediatric endocrinology oversight; at-home kits are not appropriate for this population.

Optimal Bioavailable Testosterone: What the Evidence and Longevity Medicine Say

"Normal" describes a population distribution. "Optimal" describes the range associated with the best functional and health outcomes. These two concepts do not always overlap.

Men: Where the Evidence Points

Cross-sectional data from the European Male Aging Study (EMAS), which enrolled 3,369 men aged 40 to 79, found that sexual symptoms, physical symptoms, and psychological symptoms correlated more strongly with free and bioavailable testosterone than with total testosterone [8]. Symptom thresholds emerged around a free testosterone of 64 pg/mL (approximately 220 to 250 ng/dL bioavailable by Vermeulen), below which the probability of multiple low-T symptoms rose sharply. Most longevity medicine clinicians use 200 to 400 ng/dL as a functional optimal range for bioavailable testosterone in adult men.

Cardiovascular and Metabolic Correlates

Low bioavailable testosterone in men is associated with higher visceral adiposity, insulin resistance, and increased cardiovascular risk. A meta-analysis of 11 prospective cohort studies (combined N = 11,831) published in the European Heart Journal found that men in the lowest testosterone quartile had a 36 percent higher risk of cardiovascular mortality compared with men in the highest quartile [9]. Bioavailable testosterone showed a stronger inverse association with cardiovascular events than total testosterone in three of the included cohorts.

Women: Emerging Targets

Female optimal ranges remain less defined. The Global Consensus Position Statement on female testosterone therapy (2019), endorsed by the Endocrine Society, the International Menopause Society, and the British Menopause Society, states that testosterone therapy in postmenopausal women should aim to restore levels to the upper half of the normal premenopausal range, not to supraphysiologic values [10]. For bioavailable testosterone, that translates to a rough target of 3 to 8 ng/dL in most women using physiologic-dose therapy.

A Practical Framework for Interpreting Your Bioavailable Testosterone Result

1. Confirm your SHBG was measured on the same draw. The Vermeulen calculation is only as good as its inputs.
2. Check the time of collection. A result drawn at 4 p.m. May be 15 to 25 percent lower than a morning value in the same individual.
3. Compare against age-matched reference intervals, not the laboratory's general adult range.
4. Consider symptoms. A bioavailable testosterone in the 130 to 180 ng/dL range may be "within range" for a 58-year-old man but still consistent with symptomatic hypogonadism if libido, energy, and body composition have declined.
5. Re-test before changing therapy. At-home DBS kits show intra-individual day-to-day variation of roughly 10 to 15 percent, so a single low result should be confirmed.

How SHBG Affects Bioavailable Testosterone

SHBG is the dominant variable controlling bioavailable testosterone. Conditions that raise SHBG will lower bioavailable testosterone even when total testosterone stays constant, and vice versa.

Conditions That Raise SHBG

Hyperthyroidism, liver cirrhosis, anorexia nervosa, HIV infection, and oral estrogen therapy all increase SHBG production. Aging raises SHBG independently. A man starting oral estradiol or a woman on combined oral contraceptives may see SHBG double or triple within 8 to 12 weeks, dropping bioavailable testosterone by a corresponding amount [11].

Conditions That Lower SHBG

Insulin resistance, obesity, hypothyroidism, glucocorticoid excess (endogenous or exogenous), and androgen therapy all suppress SHBG. Men with metabolic syndrome often have low-normal SHBG, which inflates their bioavailable testosterone relative to their total testosterone. This is one reason the metabolic syndrome can be present alongside total testosterone values that appear borderline rather than clearly low.

Injectable and Transdermal TRT Effects on SHBG

Testosterone cypionate and testosterone enanthate suppress SHBG dose-dependently. Weekly injections of 100 mg testosterone cypionate typically reduce SHBG by 30 to 50 percent within 8 to 12 weeks, which amplifies the rise in bioavailable testosterone beyond what total testosterone values alone would suggest. Transdermal testosterone (gel or cream) produces a smaller SHBG suppression because peak levels are lower. Monitoring bioavailable testosterone rather than total testosterone alone gives a more accurate picture of tissue androgen exposure on TRT.

Interpreting At-Home Results Alongside a Clinician

At-home DBS kits are a tool for informed self-monitoring, not a replacement for clinical evaluation. Here is how to use your results productively.

What to Bring to Your Appointment

Bring the lab report with the specific assay method listed, the time of collection, and any concurrent medications. Oral testosterone undecanoate (Jatenzo, FDA-approved 2019), topical testosterone, injectable formulations, and even over-the-counter DHEA supplements all affect the result. Tell your clinician when you last took your dose relative to the blood draw; for weekly injections, trough values (drawn 6 to 7 days post-injection) and peak values (drawn 24 to 48 hours post-injection) differ by 40 to 80 percent [12].

When to Escalate Beyond At-Home Testing

Order a full clinic panel if your at-home bioavailable testosterone is below 150 ng/dL (men) or below 1.0 ng/dL (women) and you have symptoms, if SHBG exceeds 70 nmol/L (which reduces assay accuracy), or if results are inconsistent with your clinical picture. A complete panel should include total testosterone by LC-MS/MS, SHBG, LH, FSH, prolactin, and a complete metabolic panel to evaluate liver function (which affects SHBG production).

Monitoring Bioavailable Testosterone During TRT

Testosterone replacement therapy requires serial bioavailable testosterone measurement to confirm therapeutic response and avoid supraphysiologic peaks.

Starting TRT: Baseline and First Follow-Up

Baseline bioavailable testosterone (before first dose) establishes the clinical starting point. A repeat measurement at 6 to 10 weeks captures the new steady-state on most injectable and transdermal regimens. The Endocrine Society recommends a target total testosterone in the mid-normal range (400 to 700 ng/dL) during TRT, which for most men corresponds to a bioavailable testosterone of approximately 150 to 350 ng/dL depending on SHBG [3].

Ongoing Monitoring Schedule

Once a stable dose is established, testing every 6 to 12 months is sufficient for most patients. More frequent monitoring (every 3 months) applies during the first year of therapy or after any dose change. Hematocrit should be checked at the same interval because supraphysiologic testosterone raises red blood cell production; a hematocrit above 54 percent is a dose-reduction indication per FDA labeling for testosterone products [13].

At-Home Kits for TRT Monitoring

Several telehealth platforms, including those using DBS collection, allow patients to test bioavailable testosterone, SHBG, estradiol, hematocrit, and PSA from a single finger-prick card. This bundle covers the core safety and efficacy monitoring panel for most men on TRT. Turnaround from mailing to results is typically 5 to 7 business days for LC-MS/MS processing.